We develop novel and differentiated oral small molecule therapies to patients suffering from diseases with significant unmet medical need.
We are a clinical stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
Leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
Systemic sclerosis is a rare auto-immune and severe disease which affects an estimated 170,000 patients in the US and the UK.
Inventiva is developing lanifibranor, a small molecule that has been shown to reduce fibrosis in the organs affected in SSc: the skin, lung and kidney with positive effects on lung and heart function.
We are currently investigating lanifibranor in FASST, a Phase 2b clinical trial, with results expected in Q1 2019.
Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic steatohepatitis is a severe liver disease which affects 6-8% of adults in western industrialised nations and is on the rise around the globe.
Inventiva is developing lanifibranor for the treatment of NASH and systemic sclerosis (SSc), to address all the key features of NASH: inflammation, steatosis, ballooning, and importantly fibrosis.
We are currently investigating lanifibranor in NATIVE, a Phase 2b clinical trial, with results expected in the first half of 2020.
MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.
Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.
We are currently investigating odiparcil in iMProveS, a Phase 2a clinical trial, with results expected in the second half of 2019.